Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JPM: Pharma Must Change Tone Deaf Message On Pricing

This article was originally published in Scrip

Executive Summary

When biopharma executives were asked during the 34th Annual J.P. Morgan Healthcare Conference what they thought of public concerns about prescription drug pricing, some dismissed it as a political issue and others offered the same old explanations about recovering the cost of developing innovative medicines, yet the industry appears dismayed about the ongoing uproar.

Advertisement

Related Content

Industry Tightens Drug Pricing Message, But Loose Ends Remain
BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco

Topics

Advertisement
UsernamePublicRestriction

Register

SC064263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel